CIK 0001374339
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
ProMIS Neurosciences Inc.
Sign in to watch- Ticker
- PMN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Canada (Federal Level)
- Entity type
- Operating
- Phone
- +1 416-847-6898
- Business address
- SUITE 200, 1920 YONGE STREET, TORONTO, Ontario, Canada, M4S 3E2
- Former names
- AMORFIX LIFE SCIENCES LTD
- 4 Grant or award Chief Operating Officer acquired 2,660 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 10,643 shares (grant or award)
- 4 Grant or award Principal Accounting Officer acquired 13,297 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 2,000 shares at an average $4.65 ($9,290)
- 4 Open-market buy Chief Executive Officer bought 1,000 shares at $4.94 ($4,940)
- 4 Open-market buy Director bought 3,000 shares at an average $4.63 ($13,890)
- 4 Open-market buy Director bought 1,000 shares at $5.08 ($5,075)
- 4 Open-market buy Director bought 1,000 shares at $4.98 ($4,980)
- 4 Open-market buy Director bought 1,000 shares at $5.49 ($5,486)
- 4 Open-market buy Chief Executive Officer bought 1,000 shares at $5.70 ($5,700)
- 4 Open-market buy Director bought 1,000 shares at $5.98 ($5,980)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 4,000 shares at $5.92 ($23,680)
- 4 Open-market buy Chairman and CEO bought 1,000 shares at $9.80 ($9,800)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
Page 5 of 6 · 108 filings